A detailed history of Fmr LLC transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Fmr LLC holds 2,168 shares of ITOS stock, worth $20,335. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,168
Previous 1,731 25.25%
Holding current value
$20,335
Previous $23,000 39.13%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$10.33 - $18.09 $4,514 - $7,905
437 Added 25.25%
2,168 $32,000
Q1 2024

May 13, 2024

SELL
$9.89 - $13.64 $1.38 Million - $1.91 Million
-139,811 Reduced 98.78%
1,731 $23,000
Q4 2023

Feb 13, 2024

BUY
$8.57 - $11.06 $7,533 - $9,721
879 Added 0.62%
141,542 $1.55 Million
Q3 2023

Nov 13, 2023

SELL
$10.95 - $14.6 $591 - $788
-54 Reduced 0.04%
140,663 $1.54 Million
Q2 2023

Aug 11, 2023

SELL
$12.93 - $18.05 $930,934 - $1.3 Million
-71,998 Reduced 33.85%
140,717 $1.86 Million
Q1 2023

May 11, 2023

SELL
$13.02 - $22.62 $1.85 Million - $3.22 Million
-142,283 Reduced 40.08%
212,715 $2.9 Million
Q4 2022

Feb 13, 2023

SELL
$17.77 - $21.6 $1.62 Million - $1.97 Million
-91,279 Reduced 20.45%
354,998 $6.93 Million
Q3 2022

Nov 10, 2022

BUY
$18.6 - $27.25 $280,506 - $410,957
15,081 Added 3.5%
446,277 $8.5 Million
Q2 2022

Aug 12, 2022

SELL
$16.57 - $35.1 $3.02 Million - $6.4 Million
-182,341 Reduced 29.72%
431,196 $8.88 Million
Q1 2022

May 13, 2022

SELL
$31.92 - $47.45 $5.81 Million - $8.63 Million
-181,944 Reduced 22.87%
613,537 $19.7 Million
Q4 2021

Feb 14, 2022

SELL
$26.23 - $47.86 $251,808 - $459,456
-9,600 Reduced 1.19%
795,481 $37 Million
Q3 2021

Nov 15, 2021

SELL
$23.91 - $29.58 $136,287 - $168,606
-5,700 Reduced 0.7%
805,081 $0
Q2 2021

Aug 13, 2021

BUY
$17.9 - $36.1 $14.5 Million - $29.3 Million
810,781 New
810,781 $0

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $334M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track Fmr LLC Portfolio

Follow Fmr LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.